# US 10,765,128 B2 · Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,765,128 B2 - Document ID: US10765128B2 - Status: Granted - Kind: B2 - Application number: 15/752,776 - Filed: 2016-08-19 - Published: 2019-03-14 - Granted: 2020-09-08 - Earliest claimed: 2015-08-19 - Assignees: Korea Research Institute of Bioscience and Biotechnology - Applicants: Korea Research Institute of Bioscience and Biotechnology - Inventors: Tae Sook Jeong; Ho Yong Park; Dong-Ha Shin; Myung-Sook Choi; Hua Li; Han-Young Cho; Hyeon-Seon Ji - Web page: https://patentgrep.com/patent/US10765128B2 ## CPC - A23K 10/30: from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms (obtained by microbiological or biochemical processes, e.g. using yeasts or enzymes, A23K10/10) - A23K 20/10: Organic substances - A23K 20/121: containing oxygen or sulfur as hetero atom - A23L 33/105: Plant extracts, their artificial duplicates or their derivatives - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae - A23K: FODDER - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A composition for prevention or treatment of metabolic syndrome or for antioxidation includes black soybean leaf extracts and flavonol glycoside compounds isolated thereof as active ingredients. It has been confirmed that the black soybean leaf extracts and the flavonol glycoside compounds isolated thereof effectively inhibit α-glucosidase activity; LDL oxidation and DDP-4; have excellent DPPH radical scavenging activity; inhibitory activity of reactive oxygen species (ROS) accumulation; effectively promote insulin secretion; regulate the expression of major genes; have an excellent ability to reduce a waist/hip circumference ratio; decrease the concentrations of plasma free fatty acid and plasma triglyceride; increase the concentration of plasma HDL-cholesterol; decrease an atherogenic index; increase erythrocyte catalase, SOD and GR activities; decrease erythrocyte lipid peroxide TBARS; decrease the concentrations of inflammatory cytokines MCP-1 and PAI-1, and resistin; and increase the concentration of plasma adiponectin. ## Claims ### Claim 1 A method of treating a metabolic syndrome by administering a therapeutically effective amount of a composition comprising a black soybean leaf extract to a subject in need thereof. ### Claim 2 (depends on 1) The method of claim 1, wherein said black soybean is Seoritae (G. max (L.) Merr. Seoritae) or Seomoktae (Rhynchosia nulubilis). ### Claim 3 (depends on 1) The method of claim 1, wherein said extract is extracted by using water, C1 to C2 lower alcohols or a mixture thereof. ### Claim 4 (depends on 1) The method of claim 1, wherein said metabolic syndrome is one or more selected from the group consisting of diabetes, type 2 diabetes, obesity, insulin resistance, fatty liver, hyperlipidemia, atherosclerosis, and a complication thereof. ### Claim 5 (depends on 4) The method of claim 4, wherein said complication is one or more selected from the group consisting of coronary artery disease, angina, carotid artery disease, cerebral stroke, cerebral arteriosclerosis, hypercholesterolemia, cholesterol gallstone, hypertriglyceridemia, hypertension, cataract, renal disease, neuropathy, and chronic inflammatory disorder or infection. ### Claim 6 (depends on 1) The method of claim 1, wherein said black soybean leaf extract contains at least one compound selected from the group consisting of flavonol glycoside compounds represented by following Formulas 1 to 7: ### Claim 7 (depends on 1) The method of claim 1, wherein said black soybean leaf extract inhibits α-glucosidase activity. ### Claim 8 (depends on 1) The method of claim 1, wherein said black soybean leaf extract inhibits DPP-4 (Dipeptidyl peptidase-4) activity. ### Claim 9 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases insulin secretion in a pancreatic n-cell. ### Claim 10 (depends on 1) The method of claim 1, wherein said black soybean leaf extract has LDL (low-density lipoprotein)-antioxidant activity. ### Claim 11 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases expressions of adiponectin gene and adiponectin receptor. ### Claim 12 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases expressions of GLUT-2 (glucose transporter-2) and IRS-2 (insulin receptor substrate, and decreases expressions of FOXO1 (forkhead box 01) and FOXA2 (forkhead box A2). ### Claim 13 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases expressions of PPARα (peroxisome proliferator-activated receptor α) and PPARδ (peroxisome proliferator-activated receptor δ), and decreases an expression of PPARγ (peroxisome proliferator-activated receptor γ). ### Claim 14 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases an expression of CPT-1α (carnitine palmitoyltransferase 1α) gene, and decreases expressions of ACC1 (acetyl-CoA carboxylase 1), ACC2 and FAS (fatty acid synthase) genes. ### Claim 15 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases gene expressions of insulin receptors InsR (insulin receptor), IRS-1 and GLUT-4, and decreases expressions of TNF-α (tumor necrosis factor-α). ### Claim 16 (depends on 1) The method of claim 1, wherein said black soybean leaf extract increases expressions of HSL (hormone-sensitive lipase) and UCP3 (uncoupling protein-3) genes. ### Claim 17 (depends on 1) The method of claim 1, wherein said black soybean leaf extract decreases blood concentrations of inflammatory cytokines MCP-1 (monocyte chemoattractant protein-1) and PAI-1 (plasminogen activator inhibitor-1), decreases a concentration of plasma resistin, and increases a blood concentration of adiponectin.